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Abstract
Background: In the management of bacteremia, positive repeat blood cultures (persistent bacteremia) are
associated with increased mortality. However, blood cultures are costly and it is likely unnecessary to repeat
them for many patients. We assessed predictors of persistent bacteremia that should prompt repeat blood
cultures.
Methods: We conducted a retrospective cohort study of bacteremias at an academic hospital from April
2010 to June 2014. We examined variables associated with patients undergoing repeat blood cultures, and
with repeat cultures being positive. A nested case control analysis was performed on a subset of patients
with repeat cultures.
Results: Among 1801 index bacteremias, repeat cultures were drawn for 701 patients (38.9 %), and 118 persistent
bacteremias (6.6 %) were detected. Endovascular source (adjusted odds ratio [aOR], 7.66; 95 % confidence interval [CI],
2.30-25.48), epidural source (aOR, 26.99; 95 % CI, 1.91-391.08), and Staphylococcus aureus bacteremia (aOR, 4.49; 95 % CI,
1.88-10.73) were independently associated with persistent bacteremia. Escherichia coli (5.1 %, P = 0.006), viridans group
(1.7 %, P = 0.035) and β-hemolytic streptococci (0 %, P = 0.028) were associated with a lower likelihood of
persistent bacteremia. Patients with persistent bacteremia were less likely to have achieved source control
within 48 h of the index event (29.7 % vs 52.5 %, P < .001), but after variable reduction, source control was
not retained in the final multivariable model.
Conclusions: Patients with S. aureus bacteremia or endovascular infection are at risk of persistent bacteremia.
Achieving source control within 48 h of the index bacteremia may help clear the infection. Repeat cultures
after 48 h are low yield for most Gram-negative and streptococcal bacteremias.
Keywords: Bacteremia, Bloodstream infection, Epidemiology, Blood cultures, Gram-positive bacteria,
Gram-negative bacteria
Background
Blood cultures are common investigations in the assess-
ment of a broad range of infectious syndromes, detect-
ing approximately 200,000 cases of bacteremia annually
in the United States [1]. Despite such high incidence,
studies have highlighted the low yield of blood cultures
in a number of clinical settings, including cellulitis [2],
community-acquired pneumonia [3, 4], pyelonephritis
[5, 6], and isolated fever or leukocytosis [1]. Although
the utility in these settings is debatable, there is evidence
of ongoing unrestrained blood culture use [7].
For confirmed cases of bacteremia, repeat cultures are
recommended for Staphylococcus aureus bacteremia and
infective endocarditis [8, 9]. Breakthrough bacteremia
occurs in approximately 6 % of bacteremic episodes and
is an independent predictor of death [10]. A study of
Klebsiella pneumoniae bacteremia showed that repeat
cultures were drawn in 81 % of cases despite only a 7 %
incidence of persistent bacteremia, and suggested that a
clinical scoring system could be applied to decide which
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patients warranted repeat cultures [11]. Data to guide
the use of repeat cultures for other organisms is lacking,
despite a “conventional wisdom” that they should be
avoided [8, 9].
At Sunnybrook Health Sciences Centre (SHSC), ap-
proximately 20,000 sets of blood cultures are processed
annually. In the current climate of soaring health care
costs, movements such as the Choosing Wisely campaign
are encouraging physicians to rethink the use of com-
mon investigations with questionable value [12]. Given
that the overall yield of blood cultures is approximately
4–7 % [1], the use of initial and repeat blood cultures
should continue to be scrutinized.
We evaluated the current patterns of repeat blood
culture use at our institution and the epidemiology of
persistent bacteremia. Our goal was to examine clinical
and microbiologic variables that were associated with
persistent bacteremia, and thereby identify bacteremic
episodes with high yield and low yield for repeat cul-
ture use.
Methods
Study design, setting and patients
We conducted a retrospective cohort study of adult
patients admitted to SHSC between April 1 2010 and
June 30 2014 with a first episode of bacteremia. Patients
aged <17 years were excluded. Subsequent bacteremic
episodes for the same patient were also excluded. A
nested case control study was also conducted, compar-
ing individuals with persistent bacteremia to a randomly
sampled subset of patients with cleared bacteremia.
SHSC is an academic hospital in Toronto, Canada that
services approximately 31,000 patients annually, with
824 acute care beds including 82 intensive care beds.
The study was approved by the SHSC ethics review
board.
Data sources
Patients with episodes of bacteremia were identified
using the Stewardship Program Integrated Resource In-
formation Technology (SPIRIT) database at SHSC. The
database, as previously described [13, 14], is automatic-
ally populated by health level 7 (HL7) messages from
pharmacy, microbiology and electronic patient care data-
bases for all admitted and previously admitted patients.
For the patients included in the nested case control ana-
lysis, a focused review of the patients’ charts was con-
ducted to extract more detailed clinical data regarding
the source of infection and the patients’ clinical status at
the time of repeat blood culture collection.
Blood culture collection, processing and reporting
Blood cultures at SHSC are performed using BACTEC
9240 blood culture system (Becton Dickinson Diagnostic
Instruments Systems, USA) in accordance with Clinical
Laboratory Standards Institute guidelines [9]. A blood
culture set consists of blood collected into one aerobic
and one anaerobic culture bottle, each receiving 10 mL
of blood. The number of sets collected was determined
by the ordering physician as part of usual clinical care.
Positive cultures are Gram stained and then plated on
blood agar, chocolate agar, colistin-nalidixic acid agar,
MacConkey agar and brucella agar plates. Gram-negative
colonies are identified by VITEK® 2 (model 510731-9EN1,
bioMérieux, Inc., USA), while Gram-positive colonies are
identified by various spot techniques depending on their
morphology and configuration (latex agglutination, tube
coagulase, StaphSR, etc.).
Definitions
A clinically significant bacteremia was defined as at least
one positive blood culture set with a bacterium that is
not part of the commensal skin flora. Cultures with
coagulase-negative staphylococci, Diphtheroids, or Bacil-
lus spp. were individually assessed to determine whether
they were clinically significant or contaminants. Criteria
included clinical evidence of sepsis, multiple positive
blood culture sets, or evidence of primary site of infection
with the same organism [8]. Polymicrobial bacteremia was
defined as 2 or more clinically significant bacterial species
isolated from the same blood culture set. The bacteremia
was considered hospital-acquired if the blood culture was
drawn more than 48 h after the admission time.
The index bacteremia was defined as the first clinically
significant bacteremia that occurred for a patient during
our study window. We first determined whether or not
any repeat blood cultures were sent in the interval be-
tween 2–7 days after the index bacteremia. If at least
one repeat blood culture set drawn 2–7 day after the
index bacteremia grew the same organism, the event
was defined as a persistent bacteremia. When all repeat
cultures in this window were negative, this was defined
as a cleared bacteremia. For polymicrobial index bacter-
emias, persistent bacteremia was defined as detection of
any one or more of the index pathogens from a repeat
culture during the 2–7 day window. Repeat cultures
drawn in the first 48 h were excluded from these ana-
lyses, because (1) multiple blood culture sets are often
sent as part of an initial diagnostic work-up, (2) within
48 h the clinical team would often not yet be aware of
the positivity of the original culture, and (3) this narrow
time interval would be too brief to qualify as persistent
bacteremia.
Infections were defined broadly as having an endovas-
cular, extravascular or unknown source. Endovascular
infections in this study included infective endocarditis,
infected central venous catheter, pacemaker infection
and vascular graft infection. Extravascular infections
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were those with a focus identified in tissue, organ or
body cavity based on the clinical presentation and the
results of imaging, culture or biopsy investigations.
Unknown source was the designation for those bacter-
emias for which no source could be identified based on
clinical presentation and standard investigations.
Surveillance cultures were defined as repeat cultures
drawn to document blood sterility after the initiation of
antibiotics, or those drawn in the absence of clinical
variables of instability (systemic inflammatory response
syndrome (SIRS) criteria, isolated fever (T > 38.0 °C), or
leukocytosis (WBC > 12,000)).
Covariates
Variables of interest collected in this study included: pa-
tient demographics (age, sex and comorbidities), hospital
variables (admitting service), culture variables (date and
time of blood culture collection, identities and suscepti-
bilities of isolates, timing and results of subsequent cul-
tures), infectious syndrome variables (site of primary
infection), patient variables (vital signs, leukocyte count
and physician impression at time of repeat culture as
documented in progress notes), treatment variables (tim-
ing of adequate antibiotic therapy, need and timeliness
of source control), and outcome variables (ICU admis-
sion within 72 h of index bacteremia, length of stay and
mortality). For mortality, because inclusion into the
cohort with repeated blood cultures necessitated
being alive at least 48 h after the index bacteremia,
7-day and 30-day mortality actually represent mortal-
ity between 2–7 days and 2–30 days, respectively. For
those without repeat blood cultures, 7-day mortality
had the same definition, but 30-day mortality repre-
sented 0–30 day mortality.
Statistical analysis
First, we compared patient and pathogen characteristics
among patients who did or did not undergo repeat blood
culture testing. Next, we assessed only those patients
who had repeat blood cultures drawn. We compared the
probability that, for a given covariate (i.e. E. coli as the
causative organism), a repeat culture drawn 2–7 days
after the index bacteremia would be positive (persistent
bacteremia) or negative (cleared bacteremia). Lastly, we
performed a nested case control study, comparing
patients with persistent bacteremia to an equally large sub-
set of randomly sampled patients with cleared bacteremia,
once again assessing the association between covariates
and whether the repeat cultures were positive or negative.
Please refer to the flow chart in Fig. 1 for an overview of
the different comparator groups and their sizes. Categorical
variables were compared using the Chi Square test or Fish-
er’s exact test when necessary. Continuous variables were
compared using the Wilcoxon rank sum test. Multivariable
logistic regression was performed including all variables as-
sociated with persistent bacteremia in bivariate analyses in
the nested case control analysis, with stepwise backward
selection for variable reduction until all retained variables
were statistically significant at p-value threshold <0.05.
We calculated the number of avoidable repeated blood
cultures obtained among those with no documentation of
clinical instability or deterioration, and no high yield pa-
tient or pathogen characteristics for persistent bacteremia.
We calculated a cost range using values reported in the
literature that were felt to approximate our institution,
with different cost for negative ($15–50) and positive
($67–100) cultures [15, 16]. All analyses were performed
using Microsoft Excel or SAS software (version 9.3; SAS
institute).
Results
There were a total of 2715 patients with positive blood
cultures (Fig. 1). Of these, 914 (33.7 %) were contami-
nants, leaving 1801 index bacteremias included in our
cohort. Repeat cultures were drawn for 701 (38.9 %)
patients between 2–7 days from the index event. The re-
peat culture demonstrated a persistent bacteremia in
118 patients (6.6 %). Of the 583 cleared bacteremias, 118
were randomly sampled for inclusion in the nested case
control analysis (Fig. 1).
Cohort study
Admission service
Although repeat cultures were more common among
surgical in-patients (44.2 % vs 35.5 %, p = 0.003), these
individuals were statistically more likely to have a
cleared bacteremia (46.7 % vs 32.2 %, p = 0.004) (Table 1).
In contrast, repeat cultures were less likely to be done
on medical in-patients (45.0 % vs 37.9 %, p < .001), but
persistent bacteremia was more common in this group
(55.1 % vs 34.5 %, p < .001) (Table 1).
Microbiology
Escherichia coli was the most common cause of index
bacteremia (23.3 %) (Fig. 2). The most common cause of
persistent bacteremia was S. aureus (45.8 %), followed by
Enterococcus spp. (16.9 %) (Table 1). E. coli was a rarer
cause of persistent bacteremia (5.1 % of persistent bac-
teremias, and 1.4 % of cases of index bacteremias caused
by this organism) (Fig. 2).
Repeat cultures were more commonly drawn for
Gram-positive organisms, particularly S. aureus (23.1 %
vs 8.8 %, p < .001) (Table 1). These organisms also had
an increased likelihood of causing persistent bacteremia
(45.8 % vs 18.5 %, p < .001) (Table 1). Among the various
Streptococcus spp., there was no difference in whether or
not repeat cultures were drawn, however β-hemolytic
and viridans group streptococci were more likely to have
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cleared when repeat cultures were drawn (Table 1).
Gram-negative organisms were less likely to have repeat
cultures drawn (32.2 % vs 59.4 %, p < .001), and E. coli
was significantly associated with a cleared bacteremia
(14.4 % vs 5.1 %, p = .006) (Table 1).
Outcomes
The median length of stay was longer for those with re-
peat cultures compared to those without (26 vs 12 days,
p < .001) (Table 1). Individuals who underwent repeat
cultures had 27 % mortality at 30 days (Table 1). This
was significantly higher than those with no repeat cul-
tures (11.2 %, p < .001) (Table 1). There was no differ-
ence in 30-day mortality between patients with cleared
and persistent bacteremia (Table 1).
Nested case control analysis
Population characteristics
There was no significant difference in any comorbidities
between individuals with cleared or persistent bacteremia
(Table 2). With respect to admission service, the associ-
ation between persistent bacteremia and admission to a
medical in-patient service remained significant in the
nested case control analysis (55.1 % vs 36.4 %, p = 0.004)
(Table 2). Trends in microorganism distribution between
cleared and persistent bacteremia were largely preserved.
S. aureus was associated with persistent bacteremia, while
cleared bacteremia was associated with E. coli, Streptococ-
cus pneumoniae, β-hemolytic and viridans group strepto-
cocci (Table 2).
Clinical syndrome
Endovascular infections were statistically associated with
persistent bacteremia (44.1 % vs 23.7 %, p < .001), largely
driven by central catheter and intravascular device infec-
tions (Table 3). Among extravascular syndromes, epidural
abscesses and discitis were associated with persistent
bacteremia, while genito-urinary infections were more
commonly associated with cleared bacteremia (Table 3).
Fig. 1 Distribution of patients in the cohort and nested case control analyses, according to receipt of repeat blood culture testing, and
documentation of persistent versus cleared bacteremia. NOTE: The 118 cleared bacteremia included in the nested case control analysis were
randomly sampled from the full cohort
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Clinical status when repeat cultures were drawn
A total of 28.7 % of patients were febrile at the time
of repeat culture (Table 3). Of the patients for whom
documentation regarding the physician’s impression of
their clinical status was available, only 30.3 % of
repeat cultures were drawn to work-up an unstable
patient, while the other 69.7 % were surveillance cul-
tures (Table 3). None of the patient demographic or
comorbidity characteristics were predictive of persist-
ent bacteremia (Table 3).
Antibiotics and source control
The majority of patients had appropriate empiric anti-
biotic coverage, including those with cleared and persist-
ent bacteremia (Table 4). Only 3 patients, all in the
persistent bacteremia group, had the choice of
Table 1 Characteristics of patients with bacteremia according to whether repeat cultures were obtained, and whether repeat
cultures were persistently positive














Male n(%) 576 (52.4) 442 (63.1) <0.001 361 (61.9) 80 (67.8) 0.23
Age(y) median (IQR) 71 (56.5–82) 66 (51–77) <0.001 65 (51–77) 68 (52–80) 0.26
Length of stay(d) median (IQR) 12 (5–30) 26 (12–48) <0.001 26 (12–50) 25 (12–41) 0.59
Hospital-acquired n(%) 514 (46.7) 389 (55.5) <0.001 333 (57.1) 55 (46.6) 0.036
Admitting service n(%)
Medical 495 (45.0) 266 (37.9) 0.003 201 (34.5) 65 (55.1) <0.001
Surgical 390 (35.5) 310 (44.2) <0.001 272 (46.7) 39 (33.1) 0.007
Heme-Onc 215 (19.5) 125 (17.8) 0.36 110 (18.9) 14 (11.9) 0.07
Organism n(%)
Total Gram-positive bacteria 425 (38.6) 457 (65.2) <0.001 367 (63.0) 90 (76.3) 0.006
S. aureus 97 (8.8) 162 (23.1) <0.001 108 (18.5) 53 (44.9) <0.001
Skin commensals 62 (5.6) 114 (16.3) <0.001 98 (16.8) 16 (13.6) 0.38
Enterococcus spp. 110 (10.0) 102 (14.6) 0.004 82 (14.1) 20 (16.9) 0.42
S. pneumoniae 22 (2.0) 11 (1.6) 0.506 11 (1.9) 0 0.13
Viridans group streptococci 48 (4.4) 41 (5.9) 0.156 39 (6.7) 2 (1.7) 0.031
β-hemolytic streptococci 46 (4.2) 23 (3.3) 0.33 23 (4.0) 0 0.021
S. anginosus group 31 (2.8) 11 (1.6) 0.087 10 (1.7) 1 (0.9) 0.70
Other Gram-positive bacteria 35 (3.2) 30 (4.3) 0.22 29 (5.0) 1 (0.9) 0.044
Total Gram-negative bacteria 654 (59.4) 247 (35.2) <0.001 220 (37.7) 27 (22.9) 0.002
E. coli 329 (29.9) 90 (12.8) <0.001 84 (14.4) 6 (5.1) 0.006
Klebsiella spp. 143 (13.0) 43 (6.1) <0.001 33 (5.7) 10 (8.5) 0.25
Pseudomonas spp. 45 (4.1) 32 (4.6) 0.63 27 (4.6) 5 (4.2) 0.85
AmpC-producers 102 (9.3) 59 (8.4) 0.54 53 (9.1) 6 (5.1) 0.15
Other Gram-negative bacteria 69 (6.3) 39 (5.6) 0.54 35 (6.0) 4 (3.4) 0.26
Anaerobes 86 (7.8) 34 (4.9) 0.014 32 (5.5) 2 (1.7) 0.1
Polymicrobial n(%) 107 (9.7) 75 (10.7) 0.51 66 (11.3) 9 (7.6) 0.24
Mortality n(%)
2-day 97 (8.8) - - - - -
7-day 44 (4.0) 42 (6.0) 0.053 29 (5.0) 13 (11.0) 0.012
30-day 123 (11.2) 189 (27.0) <0.001 160 (27.4) 29 (24.6) 0.52
NOTE: P values were calculated using the Chi square or Fisher’s exact test for categorical variables and Wilcoxon rank sum test for continuous variables. P value
threshold for significance was <0.05 (statistically significant values are bolded). IQR interquartile range, Heme-Onc hematology-oncology in-patient ward. Skin com-
mensals include coagulase-negative staphylococci, Bacillus spp., Diphtheroids. AmpC-producers include Serratia marcescens, Providencia stuartii, Proteus vulgaris,
Citrobacter spp., Enterobacter spp., Morganella morganii
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antibiotics influenced by the results of the repeat blood
culture. These patients all had line infections with com-
mensal skin organisms, and antibiotics were withheld
until repeat cultures demonstrated that the organism
was persistent and not a contaminant.
There was no significant difference in the total num-
ber of patients with a clinical syndrome that required
source control for adequate management (Table 4). For
those that required source control, individuals with per-
sistent bacteremia were less likely to have undergone de-
finitive management within 48 h of the index bacteremia
(22/74 (29.7 %) vs 32/61 (52.5 %), p < .001) (Table 4).
This difference was mainly driven by significant delays
for spinal/peripheral joint and thoraco-abdominal
sources of infection (Table 4).
Multivariate analysis
Multivariable logistic regression analysis was performed to
examine independent predictors of persistent bacteremia
(Table 5). Factors that were independently associated
with persistent bacteremia included male sex (ad-
justed OR [aOR] 2.59; 95 % confidence interval [CI]
1.28–5.25), admission to a medical service (aOR 2.80;
95 % CI 1.34–5.84), S. aureus bacteremia (aOR 4.49;
95 % CI 1.88–10.73), and endovascular (aOR 7.66;
95 % CI 2.30–25.48) or epidural (aOR 26.99; 95 % CI
1.91–391.08) focus of infection (Table 5).
Costs of repeat culture testing
There were a total of 1620 blood cultures drawn for the
patients included in the nested case control analysis
during their bacteremic episode. Extrapolating this to all
patients with repeat cultures, there were 4130 blood cul-
tures drawn (1131 positive and 1996 negative) at an esti-
mated cost of $105,717–$212,900 [15, 16]. Since only
69.7 % of repeat cultures were done on stable patients,
after removing individuals with appropriate indications
for repeat cultures (S. aureus bacteremia, endovascular
or epidural focus of infection, clinical deterioration),
there were 1031 inappropriate repeat cultures (134 posi-
tive, 897 negative) that could have been avoided, at a
cost savings of $22,433–$58,250.
Discussion
In this retrospective cohort study, we assessed the clin-
ical and microbiological variables associated with the
decision to repeat blood cultures for a patient with
bacteremia, and with a repeat culture remaining positive
(persistent bacteremia). Key associations with persistent
bacteremia included endovascular sources of infection
and S. aureus bacteremia, as well as the inability to
achieve source control by 48 h. Cleared bacteremia was
associated with E. coli, β-hemolytic and viridans group
streptococci, and a genito-urinary source of infection.
Our results support those of Lopez Dupla et al. [10],
demonstrating a shift in the epidemiology of persistent
bacteremia (termed breakthrough bacteremia in their
study) since the 1980s from Gram-negative intra-
abdominal infections to endovascular infections caused
by Gram-positive bacteria. The overall incidence of per-
sistent bacteremia was similar in both studies (6.6 % vs
6.1 %), and associations between persistent bacteremia
Fig. 2 Distribution of organisms causing bacteremia and persistent bacteremia. NOTE: Skin commensals include coagulase-negative staphylococci,
Bacillus spp., Diphtheroids. AmpC-producers include Serratia marcescens, Providencia stuartii, Proteus vulgaris, Citrobacter spp., Enterobacter spp.,
Morganella morganii
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and microbiologic/clinical variables were comparable
[10]. As they speculated, this change in epidemiology
likely reflects the increased prevalence of central venous
catheters in medical patients, both for acute medical
care and chronic management of malignancy and end-
stage renal disease [10]. In contrast to their study, we
distinguished between bacteremic patients that did and
did not undergo repeat cultures. This allowed us to de-
termine the prognostic significance of having a repeat
culture drawn, and to assess patterns of repeat blood
culture use. We showed that having a repeat blood cul-
ture drawn, regardless of the result, was a marker of in-
creased 30-day mortality. This suggests that there are
unique characteristics of patients at the time of repeat
culture, as determined by the ordering physician, which
prompt repeat cultures and portend worse outcome. A
similar association has been documented between mor-
tality and having an initial blood culture drawn [17].
The majority of patient and pathogen characteristics
associated with persistent bacteremia were also associ-
ated with having a repeat culture drawn, which suggests
that physicians mostly repeat cultures in situations in
which persistent bacteremia is likely to occur. In con-
trast, variables that were associated with ordering repeat
cultures but not with persistent bacteremia suggest
potential scenarios of overuse of repeat cultures. This
pattern was found for surgical in-patients as well as
bacteremia caused by β-hemolytic and viridans group
streptococci. For surgical in-patients, the tissue trauma
and peri-operative stress can itself evoke leukocytosis,
fever or SIRS, which may raise concern of infection and
prompt unnecessary blood culture use. Previous data
show blood cultures to be low yield in certain post-
operative settings [18, 19]. The overuse of repeat cul-
tures for streptococci may be explained by the decision
to work such patients up for endocarditis with multiple
blood culture sets. Our study suggests that such cultures
are low yield after the 48-h mark and should be avoided.
A better strategy in such cases would be to obtain 3 sets
of blood cultures within the first 24 h of admission, pref-
erably prior to antibiotic administration since antibiotics
decrease blood culture yield [20, 21].
Table 2 Nested case control analysis: characteristics of patients








Male n (%) 70 (59.8) 80 (67.8) 0.18
Age(y) median (IQR) 66.5 (54–77) 68 (52–80) 0.61
Comorbidities n (%)
Cardiac 41 (34.7) 45 (38.1) 0.59
Respiratory 10 (8.5) 6 (5.1) 0.30
Liver 7 (5.9) 3 (2.5) 0.22
Diabetes 24 (20.3) 34 (28.8) 0.13
Dialysis 8 (6.8) 13 (11.0) 0.25
Solid tumor 33 (28.0) 24 (20.3) 0.17
Hematologic malignancy 14 (11.9) 7 (5.9) 0.11
Burn 6 (5.1) 6 (5.1) 1.0
Polytrauma 13 (11.0) 11 (9.3) 0.67
HIV 1 (0.9) 1 (0.9) 1.0
Neutropenia 15 (12.7) 8 (6.8) 0.12
Length of stay(d) median(IQR) 24 (13–52) 25 (12–41) 0.44
Admitting service n(%)
Medical 43 (36.4) 65 (55.1) 0.004
Surgical 51 (43.2) 39 (33.1) 0.11
Heme-Onc 24 (20.3) 14 (11.9) 0.71
ICU within 72 h of bacteremia n(%) 44 (37.3) 39 (33.1) 0.54
Hospital-acquired n (%) 58 (49.2) 55 (46.6) 0.70
Polymicrobial n(%) 21 (17.8) 9 (7.6) 0.019
Organism n(%)
Total Gram-positive bacteria 77 (65.3) 90 (76.3) 0.044
S. aureus 26 (22.0) 53 (44.9) <0.001
Skin commensals 10 (8.5) 16 (13.6) 0.29
Enterococcus spp. 23 (19.5) 20 (16.9) 0.50
S. pneumoniae 5 (4.2) 0 0.03
Viridans group streptococci 11 (9.3) 2 (1.7) 0.011
β-hemolytic streptococci 5 (4.2) 0 0.03
S. anginosus group 3 (2.5) 1 (0.9) 0.31
Other Gram-positive bacteria 6 (5.1) 1 (0.9) 0.062
Total Gram-negative bacteria 44 (37.3) 27 (22.9) 0.016
E. coli 16 (13.6) 6 (5.1) 0.048
Klebsiella spp. 8 (6.8) 10 (8.5) 0.62
Pseudomonas spp. 6 (5.1) 5 (4.2) 0.76
AmpC-producing bacteria 12 (10.2) 6 (5.1) 0.14
Other Gram-negative bacteria 6 (5.1) 4 (3.4) 0.54
Anaerobic bacteria 5 (4.2) 2 (1.7) 0.28
Table 2 Nested case control analysis: characteristics of patients
with cleared versus persistent bacteremia (Continued)
7-day mortality n(%) 5 (4.2) 13 (11.0) 0.05
30-day mortality n(%) 13 (11.0) 29 (24.6) 0.006
NOTE: P values were calculated using the Chi square or Fisher’s exact test for
categorical variables and Wilcoxon rank sum test for continuous variables.
P value threshold for significance was <0.05 (statistically significant values are
bolded). IQR interquartile range, HIV human immunodeficiency virus, ICU
intensive care unit, Heme-Onc hematology-oncology in-patient ward. Skin
commensals include coagulase-negative staphylococci, Bacillus spp., Diph-
theroids. AmpC-producers include Serratia marcescens, Providencia stuartii,
Proteus vulgaris, Citrobacter spp., Enterobacter spp., Morganella morganii
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This study confirms that repeat blood cultures are low
yield in most cases of documented bacteremia, particularly
in patients receiving antibiotics. While there are few stud-
ies addressing persistent bacteremia and repeat cultures,
guidelines only recommend repeat cultures in the setting
of endocarditis, S. aureus bacteremia or if the patient has a
clinical deterioration [8, 9]. Fever alone does not necessi-
tate repeat cultures, since patients may remain febrile for
days after antibiotics have been started. Persistence of fever
was not associated with increased mortality for in-patients
with microbiologically identified infections [22]. Clinical
judgment is required to decide which patients warrant
repeat blood cultures, but our study did not detect any
clinical variables (fever, SIRS criteria, leukocytosis) to be
predictive of persistent bacteremia at the time of repeat
culture. The poor operating characteristics of these vari-
ables highlights the need for better markers in the detec-
tion and prognostication of severe bacterial infections.
Surveillance cultures are valuable for endocarditis and S.
aureus bacteremia, since the presence of persistent
bacteremia may guide decisions regarding the need for de-
finitive source control. In cases where there is concern for
clinical deterioration during treatment for bacteremia, the
other role for repeat cultures would be to identify a new
bacteremic episode with a pathogen that was not present
in the initial blood culture. Grace et al. showed this to be
a rare event, occurring in 1 out of 139 (0.72 %) bacter-
emias [20]. There was a similarly low rate in our cohort,
with 26 events (1.4 %) identified. The cause of the in-
creased mortality associated with persistent bacteremia is
not clear, but our study showed an association between
Table 3 Nested case control analysis of persistent versus
cleared bacteremia: clinical syndrome and clinical parameters









Endovascular 28 (23.7) 52 (44.1) <0.001
Endocarditis 9 (7.6) 18 (15.3) 0.066
Central line/device/graft 19 (16.1) 34 (28.8) 0.019
Extravascular 68 (57.6) 54 (45.8) 0.068
Abdominal 19 (16.1) 10 (8.5) 0.074
Cardio-respiratory 18 (15.3) 11 (9.3) 0.17
Genito-urinary 20 (16.9) 7 (5.9) 0.008
SSTI 9 (7.6) 15 (12.7) 0.20
Epidural abscess/discitis 1 (0.9) 7 (5.9) 0.036
Septic arthritis 1 (0.9) 5 (4.2) 0.121
Unknown 22 (18.6) 12 (10.2) 0.064
Clinical parameters at
time of repeat culture
[present/total (%)]
SIRS 51/105 (48.6) 40/98 (40.8) 0.27
Leukocytosis 50/118 (42.4) 48/114 (42.1) 0.97
Fever 34/106 (32.1) 25/99 (25.3) 0.28
Physician concern of instability 36/105 (34.3) 25/96 (26.0) 0.20
NOTE: P values were calculated using the Chi square or Fisher’s exact test.
P value threshold for significance was <0.05 (statistically significant values are
bolded). SSTI, skin and soft tissue infection (including cellulitis, necrotizing soft
tissue infection, cutaneous and muscular hematomas, ulcers, osteomyelitis and
surgical site infections); SIRS systemic inflammatory response syndrome
Table 4 Nested case control analysis: antibiotic and source








Appropriate antibiotics n (%)
Empiric 67 (57.8) 72 (61.0) 0.51
Guided by index culture 51 (43.2) 40 (33.9) 0.14
Guided by repeat culture 0 3 (2.5) 0.123
Source control required n (%) 61 (51.7) 74 (62.7) 0.087
Endovascular 32 (27.1) 41 (34.7) 0.21
Line removal 28 (23.7) 35 (29.7) -
PPM/ICD explantation 1 (0.9) 1 (0.9) -
Valve surgery 3 (2.5) 6 (5.1) -
Aortic graft replacement 0 1 (0.9) -
Spine and Joint 3 (2.5) 10 (8.5) 0.051
Epidural abscess/spinal 2 (1.7) 5 (4.2) -
Peripheral joint 1 (0.9) 5 (4.2) -
Thoraco-abdominal 18 (15.3) 13 (11.0) 0.34
Pericardiocentesis 0 1 (0.9) -
Empyema 2 (1.7) 2 (1.7) -
Intra-abdominal abscess 3 (2.5) 1 (0.9) -
Liver abscess 2 (1.7) 1 (0.9) -
Cholangitis 4 (3.4) 2 (1.7) -
Peritonitis 1 (0.9) 2 (1.7) -
Nephrostomy tube 1 (0.9) 2 (1.7) -
Foley removal 4 (3.4) 2 (1.7) -
ICP monitor removal 1 (0.9) 0 -
SSTI 8 (6.8) 10 (8.5) 0.62
Debridement/abscess drainage 8 (6.8) 8 (6.8) -
Amputation 0 2 (1.7) -
Source control done in 48 h n (%) 32/61 (52.5) 22/74 (29.7) <0.001
Endovascular 16/32 (50.0) 16/41 (39.0) 0.35
Spine and joint 2/3 (66.7) 0/10 0.038
Thoraco-abdominal 11/18 (61.1) 6/13 (46.2) 0.046
SSTI 3/8 (37.5) 0/10 0.069
NOTE: P values were calculated using the Chi square or Fisher’s exact test.
P value threshold for significance was <0.05 (statistically significant values are
bolded). PPM permanent pacemaker, ICD implanted cardiac defibrillator, ICP
intracranial pressure, SSTI skin and soft tissue infection
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persistent bacteremia and a failure to achieve source con-
trol at 48 h, which is one plausible explanation. Achieving
prompt source control may help to clear the bacteremia
and decrease mortality, but prospective studies are neces-
sary to address this issue.
Limitations of our study include its retrospective de-
sign, which prevented us from directly ascertaining the
indication for repeat culture testing, as well as the small
number of cases of persistent bacteremia, which limited
our ability to detect more subtle predictors of persist-
ence. Blood culture collection practices and blood cul-
ture yield may vary in hospitals with different thresholds
for testing and labs using different culturing media or
techniques. The fact that this is a single-centre study
could limit the application of our results to other set-
tings, however the fact that the detected associations
with persistent bacteremia are consistent with previous
literature suggests that our findings are not unique to
our institution. The reliance on physician documenta-
tion for aspects of the patient’s clinical status and the in-
fectious syndrome likely lead to an over-classification of
patients into the “unknown source” category. Due to the
multiple comparisons in our analysis, there is a risk of
false-positive inferences. However, due to the explora-
tory nature of the study, we opted not to apply an
adjustment for multiple comparisons [23]. Cost calcula-
tions were subject to a number of assumptions as well
as the use of pricing data not specific to our institution,
and thus we opted to report a range that is likely to
encompass the actual amount. Finally, while this study
assesses the incidence and prognostic value of persistent
bacteremia, we cannot infer whether its detection im-
proves outcomes (i.e. mortality/length of stay), or alters
therapy (i.e. antibiotics choice/duration, timing of source
control).
Conclusions
Repeat blood cultures have utility in assessing patients at
risk of persistent bacteremia, particularly those with S.
aureus bacteremia and endovascular source of infection.
Ensuring that source control is achieved within 48 h of
the index bacteremia may reduce the risk of persistence.
Whether this also reduces the excess mortality associ-
ated with persistent bacteremia should be studied fur-
ther. Common situations in which repeat blood cultures
offer low yield include bacteremic genito-urinary infec-
tions, and bacteremias caused by Gram-negative bac-
teria, viridans group and β-hemolytic streptococci.
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SHSC, Sunnybrook Health Sciences Centre; SIRS, systemic inflammatory
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Table 5 Nested case control analysis: multivariate analysis to
identify predictors of persistent bacteremia in patients with
repeat cultures
Variable Odds ratio 95 % CI P value
Sex
Male 2.59 1.28–5.25 0.008
Femalea 1.00 1.00 1.00
Admitting service
Medical in-patient 2.80 1.34–5.84 0.006
Heme-onc in-patient 1.21 0.44–3.33 0.71
Surgical in-patienta 1.00 1.00 1.00
Organism
S. aureus 4.49 1.88–10.73 <0.001
Other Gram-positive bacteria 0.80 0.35–1.82 0.59
Anaerobes 0.96 0.15–6.38 0.97
All Gram-negative bacteriaa 1.00 1.00 1.00
Source of bacteremia
Endovascular 7.66 2.30–25.48 <0.001
Epidural abscess/discitis 26.99 1.91–391.08 0.015
Other extravascular source 3.02 0.97–9.41 0.057
Unknown sourcea 1.00 1.00 1.00
NOTE: Multivariable logistic regression was performed including all variables
associated with persistent bacteremia in bivariate analyses in the nested case
control analysis, with stepwise backward selection for variable reduction until
all retained variables were statistically significant at p-value threshold
<0.05 (statistically significant values are bolded). Referent categories are
indicated with ‘a’. Heme-onc hematology-oncology in-patient ward
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